Sumitomo Mitsui DS Asset Management Company Ltd Has $5.12 Million Stock Holdings in Kenvue Inc. $KVUE

Key Points

• Sumitomo Mitsui DS Asset Management increased its stock holdings in Kenvue Inc. by 10.5%, acquiring an additional 23,191 shares, bringing its total to 244,494 shares valued at approximately $5.12 million.
• Kenvue recently reported a quarterly earnings per share (EPS) of $0.29, surpassing estimates of $0.28, while its revenue of $3.84 billion fell short of expectations.
• The company announced a quarterly dividend increase to $0.2075 per share, with an annualized dividend yield of 4.5%, despite having a dividend payout ratio of 112.16%.

Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Kenvue Inc. (NYSE:KVUE - Free Report) by 10.5% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 244,494 shares of the company's stock after purchasing an additional 23,191 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd's holdings in Kenvue were worth $5,117,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Pittenger & Anderson Inc. purchased a new stake in shares of Kenvue during the 1st quarter worth approximately $30,000. TruNorth Capital Management LLC purchased a new stake in shares of Kenvue during the 1st quarter worth approximately $36,000. Truvestments Capital LLC purchased a new stake in shares of Kenvue during the 1st quarter worth approximately $37,000. Clal Insurance Enterprises Holdings Ltd raised its position in Kenvue by 378.5% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,627 shares of the company's stock valued at $39,000 after purchasing an additional 1,287 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich raised its position in Kenvue by 120.6% in the 1st quarter. Bank Julius Baer & Co. Ltd Zurich now owns 1,699 shares of the company's stock valued at $41,000 after purchasing an additional 929 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Kenvue Stock Performance

Shares of NYSE KVUE traded up $0.73 during trading hours on Tuesday, reaching $17.70. The stock had a trading volume of 22,577,299 shares, compared to its average volume of 18,997,654. The business's fifty day moving average is $20.77 and its two-hundred day moving average is $22.00. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.98 and a quick ratio of 0.68. The company has a market cap of $33.96 billion, a price-to-earnings ratio of 23.94, a PEG ratio of 2.63 and a beta of 0.83. Kenvue Inc. has a twelve month low of $16.89 and a twelve month high of $25.17.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.28 by $0.01. Kenvue had a return on equity of 20.06% and a net margin of 9.37%.The firm had revenue of $3.84 billion during the quarter, compared to analyst estimates of $3.94 billion. During the same period in the prior year, the company posted $0.32 earnings per share. The business's revenue for the quarter was down 4.0% compared to the same quarter last year. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, research analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, August 27th. Investors of record on Wednesday, August 13th were issued a $0.2075 dividend. This is a positive change from Kenvue's previous quarterly dividend of $0.21. This represents a $0.83 annualized dividend and a yield of 4.7%. The ex-dividend date was Wednesday, August 13th. Kenvue's dividend payout ratio (DPR) is 112.16%.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on KVUE. Evercore ISI cut their price objective on shares of Kenvue from $23.00 to $18.00 and set an "in-line" rating for the company in a research report on Tuesday. Citigroup reissued a "neutral" rating on shares of Kenvue in a research note on Tuesday. Zacks Research raised shares of Kenvue to a "strong sell" rating in a research note on Monday, August 11th. Barclays decreased their target price on shares of Kenvue from $23.00 to $22.00 and set an "equal weight" rating on the stock in a research report on Tuesday, July 15th. Finally, Bank of America decreased their target price on shares of Kenvue from $27.00 to $25.00 and set a "buy" rating on the stock in a research report on Tuesday, July 15th. Five investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average price target of $23.63.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.